ライフサイエンスコーパス: exact test

1 and 0.1%, respectively (P=0.002 by Fisher's exact test).

2 postimmunization sera (P = 0.0008, Fisher's exact test).

3 CHDs (p = 3.30 x 10(-2), two-tailed Fisher's exact test).

4 esponse to interferon therapy (P=1.0, Fisher exact test).

5 e non-ischemic patients (P = 0.005, Fisher's exact test).

6 tigated (ancova, Mann-Whitney U-test, Fisher exact test).

7 PCS group (1/822 [0.12%]; P = 0.0002, Fisher exact test).

8 ncing progression to PCa (P = .014, Fisher's exact test).

9 low eyes only in 3 cases (p = 0.13, Fisher's exact test).

10 = 0.026), or SFN group (P = 0.002 by Fisher exact test).

11 6.25 [95% CI, 1.78-21.93]; P = .001, Fisher exact test).

12 sumed microvascular cause (P = 0.003, Fisher exact test).

13 orted never wearing glasses (P<0.001, Fisher exact test).

14 s or oculoplastic surgeons (P<0.0001, Fisher exact test).

15 , and number of preventable failures (Fisher exact test).

16 ere in the slow DT group (P<0.0002; Fisher's exact test).

17 onfidence intervals of 0.003%-0.56% (Fischer exact test).

18 he same gene in controls (p = .023; Fisher's exact test).

19 or outcomes (P < .01, by the 2-tailed Fisher exact test).

20 ere in the slow DT group (P<0.0001; Fisher's exact test).

21 tory of breast carcinoma (P = .007, Fisher's exact test).

22 um-sensitive recurrences (P = .003, Fisher's exact test).

23 ined (1.6% versus 4.7%, P = 0.02 by Fisher's exact test).

24 .7%) primary carcinomas (P = .0003, Fisher's exact test).

25 ut linkage evidence (P=2x10(-17) by Fisher's exact test).

26 ths 12 to 18 of treatment (p = 0.017, Fisher exact test).

27 .2% in the placebo arm (P = .768 by Fisher's exact test).

28 mmunoreactive for serotonin (P < .01, Fisher exact test).

29 n PDACs without dMMR or MSI (P = .08; Fisher exact test).

30 -augmented reinforcement (P < 0.0001; Fisher exact test).

31 rta and tetralogy of Fallot (P=0.002; Fisher exact test).

32 tive HPV results (48% vs. 0%; P=0.06, Fisher exact test).

33 hout (p = 3.12 x 10(-3), two-tailed Fisher's exact test).

34 of those with UC >1 year (P = .04, Fisher's exact test).

35 with none in the controls (P=0.0005, Fisher exact test).

36 ent to a CSF reservoir (P < 0.0001, Fisher's exact test).

37 nterval, 1.56 to 2.86; P=1.68x10(-6) (Fisher exact test).

38 antly associated with pCR (P = 0.007; Fisher exact test).

39 ARC groups were compared by using the Fisher exact test.

40 in the matched subgroups by using the Fisher exact test.

41 e compared across groups by using the Fisher exact test.

42 les were compared using chi-square/Fischer's exact test.

43 pared categorical variables using the Fisher exact test.

44 rs7848647 SNP was assessed by the Fischer's exact test.

45 d BAP1 genes were tested by using the Fisher exact test.

46 d with Wilcoxon's rank sum test and Fisher's exact test.

47 ical management was assessed with the Fisher exact test.

48 is using analysis of variance and the Fisher exact test.

49 re compared by using either chi(2) or Fisher exact test.

50 isons of regimens were assessed using Fisher exact test.

51 nce of mutations was compared using Fisher's exact test.

52 performed with the Student t test and Fisher exact test.

53 n proportions were analyzed using the Fisher exact test.

54 assessed with the Pearson chi(2) or Fishers exact test.

55 nd genomics were studied by using the Fisher exact test.

56 ups in proportions were assessed by Fisher's exact test.

57 rating characteristic curves, and the Fisher exact test.

58 ication rates were compared using the Fisher exact test.

59 compared using the chi-square test or Fisher exact test.

60 = 0.12) and 3 months treatment (p = 0.22) by Exact test.

61 follow-up period was compared using Fisher's exact test.

62 ssessed with the use of a one-sided Fisher's exact test.

63 tical analysis was performed with the Fisher exact test.

64 o-sample test of proportions, and the Fisher exact test.

65 r by using either the chi(2) or the Fisher's exact test.

66 ed and compared by using a two-tailed Fisher exact test.

67 just for sex and age, and a two-sided Fisher exact test.

68 between groups was compared using the Fisher exact test.

69 ompared across sequences by using the Fisher exact test.

70 tical analysis was performed with the Fisher exact test.

71 n patterns were analyzed by using the Fisher exact test.

72 using Chi-square test or Univariate Fisher's exact test.

73 those with sporadic CCM by using the Fisher exact test.

74 subtype ( P = .383), as assessed by Fisher's exact test.

75 variables were compared by using the Fisher exact test.

76 ategorical data were evaluated with Fisher's exact test.

77 ded vessels for each vessel type with Fisher exact test.

78 Associations were tested with the Fisher exact test.

79 ype frequencies were compared using Fisher's exact test.

80 the Mann-Whitney-Wilcoxon, chi(2), or Fisher exact test.

81 ical variables were compared with the Fisher exact test.

82 rank tests, Mann-Whitney U tests, and Fisher exact tests.

83 ment were analyzed using log-rank and Fisher exact tests.

84 ommended care was compared by using Fisher's exact tests.

85 compared by race and by sex, using Fisher's exact tests.

86 re analyzed using the Chi-squared and Fisher exact tests.

87 lary lymph node status with chi(2) or Fisher exact tests.

88 ations included linear regression and Fisher exact tests.

89 gression, 2-sample t, log-rank, and Fisher's exact tests.

90 ng more than 3400 cases using chi and Fisher exact tests.

91 ng the Student t, Pearson chi(2), and Fisher exact tests.

92 operating characteristic (ROC) analysis, and exact tests.

93 oxon signed-rank, Mann-Whitney U, and Fisher exact tests.

94 ng ANOVA, Wilcoxon Rank Sum, chi, and Fisher Exact tests.

95 stics were examined with chi(2) and Fisher's exact tests.

96 using generalized additive models and Fisher exact tests.

97 -Whitney U, Wilcoxon signed rank, and Fisher exact tests.

98 and women (51% and 54%, respectively; Fisher exact test =0.39; equivalence P=0.0002).

99 effect of SHUTi versus HealthWatch (Fisher's exact test=0.52; p=0.32).

100 The Fisher exact test (2-tailed) was used to compare proportions, S

101 ates of adverse events using the conditional exact test, a modified vaccine cohort risk interval meth

102 ficantly associated with c.8057G>A (Fisher's exact test, adjusted p value < 0.0001).

103 al leakage was analyzed by chi(2) and Fisher exact tests (alpha = 5%).

104 istic analyses Mann-Whitney U-test, Fisher's exact test and binary logistic regression were used.

105 omparison methods, e.g. chi 2 test, Fisher's exact test and Binomial test.

106 eristics and perceived burden using Fisher's exact test and bivariate modified Poisson regression.

107 The Fisher exact test and exact logistic regression were used to co

108 variables were evaluated by using the Fisher exact test and linear models with generalized estimating

109 mparisons were conducted by using the Fisher exact test and log-rank test.

110 Fisher exact test and logistic regression models were used for

111 Comparisons were made by using the Fisher exact test and Mann-Whitney test, where appropriate, wit

112 Fisher exact test and multivariate regression were used to anal

113 A 2-tailed Fisher exact test and paired Student t test were used for stati

114 unt: the chi(2) test, likelihood ratio test, exact test and permutation test.

115 ttransplant 6MWD were evaluated using Fisher exact test and Spearman correlation.

116 The Fisher exact test and Student t test analysis were performed an

117 y used gene set enrichment methods, Fisher's exact test and the binomial test implemented in Genomic

118 atistical analysis was performed with Fisher exact test and two-sample z test.

119 n both arms were compared using the Fisher's exact test and Wilcoxon Rank Sum test.

120 data analysis was performed using the Fisher exact test and Wilcoxon rank-sum test.

121 k factors were compared between groups using exact tests and general linear modeling.

122 Fisher exact tests and Kaplan-Meier methods were used to analyz

123 Fisher exact tests and Kaplan-Meier methods were used to analyz

124 th 2-sided Wilcoxon rank-sum, chi(2), Fisher exact tests and logistic regression (5% type I error rat

125 The results were analyzed using Fisher exact tests and multivariable logistic regression.

126 d with concordance were assessed with Fisher exact tests and tests for trend.

127 g hierarchic regressions or chi(2) or Fisher exact tests and with repeated-measures analysis of varia

128 equent in female recipients (P=0.007, Fisher exact test) and African American recipients (P<0.001) an

129 ases and 0.9% of controls; P = 0.002, Fisher exact test) and glaucoma (14.3% of cases and 7.2% of con

130 y superior to the EIA (P, <0.001 by Fisher's exact test) and to the GDH-EIA-CCCN algorithm (P, 0.0363

131 .0001, and P = 0.004, respectively, Fisher's exact test), and the sensitivity of GDH algorithms for r

132 were compared by using the chi(2) or Fisher exact test, and 95% confidence intervals (CIs) were calc

133 ndependent samples t test, x(2) test, Fisher exact test, and Cohen k.

134 ed using Wilcoxon rank-sum tests, the Fisher exact test, and Kaplan-Meier analysis.

135 was compared with the Pearson chi2 or Fisher exact test, and lesion sizes were compared with the Wilc

136 The heteroscedastic t test, Fisher exact test, and Mann-Whitney test were used for statisti

137 chi(2) test, Fisher exact test, and Mann-Whitney U test were used to compare

138 Chi-square analysis, Fisher's exact test, and multivariable logistic regression were u

139 compared with the chi(2) statistic or Fisher exact test, and multivariate analysis was performed with

140 he Wilcoxon rank sum test, two-tailed Fisher exact test, and multivariate logistic regression analysi

141 The Student t test, the Fisher exact test, and multivariate logistic regression were us

142 e thorax by using the Student t test, Fisher exact test, and Pearson correlation.

143 ncluded use of the two-sample t test, Fisher exact test, and Spearman correlation.

144 were performed with chi-square test, Fisher exact test, and t tests.

145 late-onset FCD was evaluated with the Fisher exact test, and the coding exons and exon-intron boundar

146 essed univariably by using chi tests, Fisher exact tests, and logistic regression models.

147 Chi-square tests, Fisher exact tests, and multivariate logistic regression were u

148 s such as Pearson chi-square test and Fisher Exact test are single test methods and do not work on co

149 ases, was compared with the chi(2) or Fisher exact test, as appropriate.

150 se who did not by using the chi(2) or Fisher exact test, as appropriate.

151 In this study, we proposed a new exact test based on the translation of rate comparison t

152 138 non-GCB cases examined (P = .008, Fisher exact test) but was present at low incidence in follicul

153 corticosteroid treatment (P = 0.002, Fisher exact test), but not with sclerosing inflammation presen

154 usted the null distribution for the Fisher's exact test by weighting the identification probability o

155 cteristics were compared by chi(2) or Fisher exact test (categorical variables) or Wilcoxon rank-sum

156 We used two-tailed Mann Whitney U exact tests, chi(2), and Fisher's exact tests to analyse

157 Fisher exact tests compared planned adjuvant treatment duration

158 ologic features (50% vs. 12%; P=0.07, Fisher exact test) compared with tumors showing negative result

159 ent groups were compared by using the Fisher exact test; continuous variables were compared by using

160 ces in frequency were assessed with a Fisher exact test corrected for multiple comparisons.

161 tatistical analysis, evaluated by the Fisher exact test, did not show a significant postoperative dif

162 for association with CPM by using the Fisher exact test, exact chi(2) test, and multivariate logistic

163 Fisher's exact test examined the effect of diagnosis on rs1625579

164 Overlap statistics, such as Fishers Exact test (FET), are often employed to assess these ass

165 -operating-characteristic analyses or Fisher exact test for 2 x 2 contingency tables using subsequent

166 rating-characteristic analyses and by Fisher exact test for 2 x 2 contingency tables.

167 icance level (type I error) of 0.05 using an exact test for a binomial proportion.

168 sample size calculation method based on the exact test for assessing differential expression analysi

169 We formulate a weighted exact test for assessing the significance of mutual excl

170 essed by means of the Pearson chi2 or Fisher exact test for categorical variables and the two-sample

171 tical analysis was performed with the Fisher exact test for categorical variables or the Wilcoxon ran

172 us variables and Pearson chi2 test or Fisher exact test for categorical variables.

173 Using Fisher's exact test for comparing the numbers of cases and contro

174 We performed the Fisher exact test for comparison of categorical values and Wilc

175 for quantitative data, and chi(2) or Fisher exact test for qualitative data.

176 test, chi2 tests of proportions, and Fisher exact test for small sample cross tables.

177 22q11.2 deletions found, using the Fisher's exact test for the independent case-control studies and

178 ey tests for continuous variables and Fisher exact tests for categorical data.

179 Fisher exact tests for categorical variables, t test for contin

180 test that is a more powerful version of the exact test in edgeR.

181 (38% vs. 13%, P=0.04 by a two-sided Fisher's exact test in the A5340 trial; and 80% vs. 13%, P<0.001

182 80% vs. 13%, P<0.001 by a two-sided Fisher's exact test in the NIH trial) but the difference was not

183 than those with T2a lesions (P = .02, Fisher exact test) in the alternative staging system.

184 was estimated using three methods: Fisher's exact test, index of association (IA) and Hedrick's D'.

185 Statistical analysis (Fisher's exact test) indicated there was no significant differenc

186 ysis (p = 2.68 x 10(-4), two-tailed Fisher's exact test), indicating that the SLC2A3 duplication migh

187 at the X chromosome, typically the chi(2) or exact test is applied to the females only, and the hemiz

188 tor analyses were performed using the Fisher exact test, log-rank test, and hazard ratio (HR).

189 Fisher exact test, log-rank test, and Mann-Whitney U test were

190 d genitourinary cases using chi(2) or Fisher exact test, Mann-Whitney test, and logistic regression.

191 or statistical analysis, chi(2) test, Fisher exact test, Mann-Whitney U test, and Wilcoxon test were

192 We applied exact testing methods to examine distributions of DNA se

193 y U test, independent samples t test, Fisher exact test, multivariate logistic regression analysis of

194 were compared by using chi(2) tests, Fisher exact tests, odds ratios (ORs), and confidence intervals

195 of each incidental finding, performed Fisher exact test or chi-square test for categorical variables

196 ore and after the intervention, using Fisher exact test or chi2.

197 and symptomatic patients by using the Fisher exact test or the Wilcoxon-Mann-Whitney test, as appropr

198 rtment and prognostic factors using Fisher's Exact test or with patient survival over 20 years using

199 s and means were compared using chi2, Fisher exact test, or t test as appropriate.

200 , respectively (IPV versus control: Fisher's exact test P < 0.001).

201 ntly reduced at 1, 12 and 52 weeks (Fisher's Exact Test p = 0.018, chi(2) = 5.1 p = 0.02 and chi(2) =

202 opathic focal childhood epilepsies (Fisher's exact test P = 2.1 x 10(-4)).

203 93 cases versus 32/65,046 controls; Fisher's exact test P = 2.83 x 10(-6), odds ratio = 26.2, 95% con

204 k from a single dairy (odds ratio, 8; Fisher exact test P value = .023).

205 secondary groups (11/49 vs 211/230: Fisher's exact test p<0.0001).

206 variants was significantly higher (Fisher's exact test P-value 0.0001) in cases (10/1318 = 0.75%) th

207 tion (44% of men versus 48% of women; Fisher exact test P=0.56; equivalence P=0.041).

208 IKZF1, and Hispanic/Latino ethnicity (Fisher exact test, P < .001 for each).

209 9 of 3402) from May to November 2016 (Fisher exact test, P < .001; odds ratio [OR], 57; 95% CI, 9.8-2

210 .4% [47 of 739] vs 0.5% [12 of 2627]; Fisher exact test, P < .001; OR, 15.1; 95% CI, 7.9-33.4).

211 ni anemia protein FANCD2 (corrected Fisher's exact test, P < 0.0007).

212 conversion to dementia over 2 years (Fisher exact test, P = .05).

213 l arm vs 92 (58%) in the control arm (Fisher exact test, P = .66).

214 t 3 days on the numeric rating scale (Fisher exact test, P = 0.0026), Patient-Oriented Eczema Measure

215 mpared with young contacts (P = 0.02, Fisher exact test, P = 0.01, Wilcoxon rank-sum, respectively).

216 ) or the DNA-binding forkhead domain (Fisher exact test, P = 0.021).

217 FTAAD compared with STAAD patients (Fisher's exact test, p = 0.03).

218 colonizing AE cases versus controls (Fisher exact test, P = 0.03).

219 nts with type II diabetes mellitus (Fisher's exact test, p = 0.035).

220 n between GEP class 2 and monosomy 3 (Fisher exact test, P<0.0001), 54 of 260 tumors (20.8%) were dis

221 ch aneuploidy was more common (69%; Fisher's exact test, P=0.0033).

222 ed with 38% in the wait-list group (Fisher's exact test, P=0.01).

223 reported with loss of asthma control (Fisher exact test; P = .003); overweight/obese children more of

224 67 ears with elevated protein; 96%)(Fisher's exact test; P<0.0001) in both normal and hearing loss ea

225 loss (32/34 hearing loss ears; 94%)(Fisher's exact test; P= .005).

226 we found a significant (P < 0.0001, Fisher's exact test) reduction in the number of edematous episode

227 seizures after presentation (P = .01; Fisher exact test), remote symptomatic seizures, and epilepsy (

228 tic regression, Welch t test, Z test, Fisher-exact test, Shapiro-Wilk test, and receiver operating ch

229 l analysis was performed by using the Fisher exact test, Student t test, and Wilcoxon signed-rank tes

230 any) was significantly (P = 0.0096, Fisher's exact test) superior to orally administered drugs in red

231 g descriptive statistic, chi(2) test, Fisher exact test, t test, and repeated-measures analysis of va

232 n R package that implements an unconditional exact test that is a more powerful version of the exact

233 Exact tests that include males are shown to have a bette

234 The two-tailed Fisher exact test, the Breslow-Day test, and kappa statistics w

235 DPRP provides three methods: the Fisher's Exact Test, the Kolmogorov-Smirnov test and the BASE alg

236 on bisulfite-seq with P-values from Fisher's exact test, tiled methylation probes using a linear mode

237 We used Fisher's exact test to compare unadjusted attack rates according

238 N-glycosylation motif, and performs Fisher's exact test to detect potential positive or negative amin

239 an be viewed as a generalization of Fisher's exact test to ternary variables.

240 Whitney U exact tests, chi(2), and Fisher's exact tests to analyse the data.

241 We used chi(2) and Fisher's exact tests to compare categorical variables and the t t

242 nterovirus D68 using the two-tailed Fisher's exact test, two-sample unpaired t test, and Mann-Whitney

243 d with absence of disease (P=0.029, Fisher's exact test, two-sided, verified by permutation to estima

244 The Fisher 2-tailed exact test, unpaired t tests, and age- and sex-adjusted

245 testing for categorical variables (Fisher's exact test used for violations of Cochran's assumptions)

246 s from the control group (p < .001 by Fisher exact test, using a maximum biofilm thickness of 30 mum

247 son of proportions was made using the Fisher exact test, using an alpha risk of 0.05 as clinically si

248 Because the 1-tailed P value from the Fisher exact test was <.001, which crossed the superiority boun

249 p with our prediction; and a modified Fisher Exact test was implemented to measure how well our predi

250 A Fisher exact test was performed to assess the statistical signi

251 A 2-tailed Fisher exact test was the statistical method used.

252 uantitative parameters, the chi(2) or Fisher exact test was used for qualitative parameters, and kapp

253 Fisher's exact test was used for the primary end point, and exten

254 Fisher exact test was used to analyze the association of testic

255 A 2-tailed Fisher exact test was used to assess for differences in ocular

256 The Fisher exact test was used to compare complication rates, and t

257 Fisher's exact test was used to compare differences between group

258 used to compare biopsy time, and the Fisher exact test was used to compare lesion type distribution

259 The Fisher's exact test was used to compare patient groups.

260 McNemar's test or Fisher exact test was used to compare proportions.

261 The Fisher exact test was used to compare proportions; the Student

262 The Fisher exact test was used to compare rates of disease-related

263 The Fisher exact test was used to compare results for fetuses image

264 The Fisher exact test was used to compare results from this study a

265 The Fisher exact test was used to compare serotonin immunoreactivit

266 The Fisher exact test was used to compare the percentage of seniors

267 Fisher exact test was used to compare the proportion of CMV vir

268 Fisher's exact test was used to compare the proportion of those w

269 The Fisher exact test was used to compare the risks of stroke, deat

270 The Fisher exact test was used to compare the two groups.

271 The Fisher exact test was used to determine differences between gro

272 The Fisher exact test was used to evaluate significance; 95% confid

273 The Fisher exact test was used to evaluate the significance of flow

274 Fisher exact test was used to examine the relationship between

275 Fisher's exact test was used to screen for association with VTE;

276 Fishers exact test was used to test for statistically significan

277 The Fisher exact test was used.

278 eria lactamica (P < 0.002) (2-sided Fisher's exact test) was more likely in the smaller, more densely

279 A significant difference (P<0.05, Fisher exact test) was observed regarding the p53 genotype freq

280 Using Levene's exact test, we reject Hardy-Weinberg in both populations

281 Pearson chi(2) test and/or Fisher exact test were used to assess differences in reporting

282 Mann-Whitney U test and Fisher exact test were used to assess group differences.

283 -Altman plot, kappa statistics, and Fisher's exact test were used to assess intra- and interobserver

284 bootstrapping and the McNemar test or Fisher exact test were used to compare sensitivity, specificity

285 llis H test, Mann-Whitney U test, and Fisher exact test were used to compare the groups, with Bonferr

286 Wallis test, Mann-Whitney U test, and Fisher exact test were used to look for statistically significa

287 The chi(2) test or Fisher exact test were used, as appropriate, for categorical da

288 Wilcoxon rank-sum and Fisher exact tests were performed.

289 etric variables, while the chi(2) and Fisher exact tests were used for comparison of categoric data.

290 The chi(2) and Fisher exact tests were used to assess differences in proportio

291 continuous variables and t-tests or Fisher's exact tests were used to compare treatment groups.

292 Fisher's exact tests were used to compare, by frailty status, per

293 chi2 Statistics and Fisher exact tests were used to evaluate differences in disease

294 n agents were made by using chi(2) or Fisher exact test, where appropriate.

295 analyzed with Pearson chi(2) tests or Fisher exact tests, while continuous variables were analyzed wi

296 ups were compared by using t test and Fisher exact test with a Bonferroni correction applied for mult

297 and CISs are also identified using Fisher's exact test with multiple testing correction.

298 s strongly associated (P < 2e-16 by Fisher's exact test) with nucleosome-free chromatin.

299 Fisher's exact test, with correction for multiple comparisons, wa

300 ce was determined by chi-square and Fisher's exact tests, with a false discovery rate correction.